CAR-T 疗法与双特异性 T 细胞衔接器在血液肿瘤中的心脏毒性特征

Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers.

Tisagenlecleucel 与严重和致命的不良心脏事件相关，在 DLBCL 患者中，与 axicabtagene ciloleucel 相比，低血压的致死率更高，但在儿童 ALL 患者中，与 blinatumomab 相比，低血压致死率相似。

CAR-T 治疗后血液肿瘤患者耶氏肺孢子菌肺炎（PcP）的结局

Outcome of Pneumocystis Jirovecii pneumonia (PcP) in post-CAR-T patients with hematological malignancies.

PcP 可在使用不同 CAR-T 产品后发生，免疫细胞的长期耗竭似乎与 PcP 相关。

axicabtagene ciloleucel 或 brexucabtagene autoleucel CAR-T 细胞治疗后的细胞因子释放综合征与免疫效应细胞相关神经毒性综合征：国际血液与骨髓移植研究中心数据

Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Ch

嵌合抗原受体（CAR）修饰 T 细胞治疗急性髓系白血病：局限与展望

Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations.

CAR-T 细胞疗法：授权治疗中心与社区肿瘤科医生的合作

CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists.

血栓事件是 CAR-T 细胞治疗的不常见毒性

Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.

缩短 CAR-T 细胞治疗等待时间的价值：来自 tisagenlecleucel 治疗弥漫大 B 细胞淋巴瘤随机对照试验数据的证据

Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Di

延迟不仅影响了 CAR-T 治疗的可及性，也影响了治疗效果。我们的结果强调了加快治疗可及性的生存获益，并可能有助于解释在不同国家观察到的 CAR-T 疗效差异。

CAR-T 细胞治疗后的疾病特异性结局

Disease-specific outcomes after chimeric antigen receptor T-cell therapy.

斯洛文尼亚成人 DLBCL 患者的 CAR-T 治疗：结局与不良事件预测评分评估

CAR T therapy in adult DLBCL patients in Slovenia: Evaluation of predictive scores for outcomes and adverse events.

溶瘤病毒与 CAR-T 细胞基因治疗的进展及治疗相关分组

Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.